Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)

Inclusion Criteria: * Adults 18 years to ≤ 65 years of age with clinical diagnosis of DLE (and at least half of patients with a diagnosis of SLE) as determined by the Principal Investigator by medical history and physical exam. * Able to understand consent procedure * Able to comply with protocol activities * Have had a diagnosis of biopsy proven DLE for at least 6 months prior to Visit 1 (Baseline/Day 1). * At Screening and Visit 1 (Baseline/Day 1), have had DLE covering at least 5% of total body surface area (BSA) or SLE with DLE covering at least 2% of BSA as determined by the hand print method (one palm is equivalent to 1% BSA). Exclusion Criteria: * Patients not able to understand consent procedure * Patients unable to comply with protocol activities * Other skin conditions at Baseline that would interfere with evaluation of DLE. * Topical corticosteroid within the past 2 weeks * Systemic therapy is allowed if on a stable dose and using for at least 3 months -background therapies outlined in Protocol * Concomitant use of moderate to potent inhibitors and inducers of CYP3A4/5 * Women who are pregnant or wish to become pregnant, or who are lactating. Women of childbearing potential must use effective contraceptive methods in order to participate in tofacitinib clinical studies * History of infection requiring hospitalization, parenteral antimicrobial therapy within 6 months prior to first dose of study drug or history of infection requiring antimicrobial therapy within 2 weeks prior to first dose of study drug